News
Kairos Pharma
KAPA · NYSE American
$0.5837+$0.0136 (+2.39%)TodayMarket closed ·
Prev close $0.5701
Latest news
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- NewsVandana Singh
Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer
- Press releaseBusiness Wire
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
- Press releaseBusiness Wire
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
- Press releaseBusiness Wire
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsRishabh Mishra
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Slip Ahead of Data-Heavy Week, Nvidia Earnings, and Jackson Hole—BABA, PMI, BIRK in Focus (UPDATED)
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Applied Optoelectronics, PDD Holdings And 3 Stocks To Watch Heading Into Monday
- Press releaseBusiness Wire
Kairos Pharma Announces 1-for-7 Reverse Stock Split
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseBusiness Wire
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
- NewsMohd Haider
Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving?
- Press releaseBusiness Wire
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
- Press releaseBusiness Wire
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
- Press releaseBusiness Wire
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award
- Press releaseBusiness Wire
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseBusiness Wire
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
- Press releaseBusiness Wire
Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
- Press releaseBusiness Wire
Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
- Press releaseBusiness Wire
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseBusiness Wire
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseBusiness Wire
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
- Press releaseBusiness Wire
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseBusiness Wire
Kairos Pharma Provides Shareholder Update
- Press releaseBusiness Wire
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
- Press releaseBusiness Wire
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
- Press releaseBusiness Wire
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
- NewsAvi Kapoor
Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views
- NewsAvi Kapoor
Dow Falls Over 100 Points; JPMorgan Posts Upbeat Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.